Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of E10H autologous NK cells plus IgG1 antibody and chemotherapy as first-line treatment for advanced gastrointestinal cancers
CTR20260775Phase 2Active
- Sponsor
- Guangzhou Doublle Bioproduct Co., Ltd.
- Start
- Jul 2026
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of E10H autologous natural killer cell injection in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, colorectal cancer (CRC), sponsored by Guangzhou Doublle Bioproduct Co., Ltd.. Started Jul 2026; status: active.
02
Drugs
E10H autologous natural killer cell injection
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20260775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260775.